C17orf77 Inhibitors
C17orf77 Kinase inhibitors such as Staurosporine and U0126 are selected based on the common regulatory mechanism of protein phosphorylation, which is a widespread method of controlling protein function. Inhibition of kinases can, therefore, have far-reaching impacts on protein function and interaction networks. LY294002 and Rapamycin are chosen for their roles in inhibiting critical signaling pathways like PI3K/AKT and mTOR, respectively. These pathways are integral to processes such as cell growth, survival, and metabolism, and their inhibitors can broadly affect protein function within these pathways.
Proteasome inhibitors, Bortezomib and MG132, are included on the premise that the ubiquitin-proteasome system plays a critical role in protein degradation. By preventing protein degradation, these inhibitors can lead to an increase in the cellular levels of numerous proteins, potentially including C17orf77. The selection of these inhibitors is based on the principle of preventing the turnover of cellular proteins, hence possibly affecting the levels of C17orf77 indirectly.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a wide range of protein kinases, potentially affecting the phosphorylation state of C17orf77 if it is kinase-regulated. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor which can affect the PI3K/AKT signaling pathway; could affect C17orf77 if it is involved in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which can inhibit the mTOR signaling pathway; might impact C17orf77 expression if it is mTOR-regulated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor which can block the MAPK/ERK pathway and might affect C17orf77 activity or stability if it interacts with this pathway. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
A Hedgehog signaling pathway inhibitor; could influence C17orf77 if it is part of the Hedgehog pathway or regulated by it. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-β receptor kinase which can block TGF-β signaling; might affect C17orf77 if it is involved in TGF-β signaling. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
An inhibitor of Wnt production; could downregulate C17orf77 if it is Wnt-responsive. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK which might modulate C17orf77 if it is regulated by the JNK signaling pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor which could indirectly affect the degradation of C17orf77, potentially increasing its cellular levels. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
A pan-caspase inhibitor that can prevent apoptosis; could stabilize C17orf77 if it is prone to degradation during apoptosis. | ||||||